Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • Myelodysplastic Syndromes (MDS)
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
      • Factors associated with young adults opting out of donation for HCT may provide insights into donor availability
      • Alternative donor HCT may yield comparable outcomes and expand access for myelofibrosis patients
      • Younger matched unrelated donors may reduce relapse risk after allogeneic HCT compared to using older matched sibling donors
      • Allogeneic HCT may be a better option for older patients with AML than conventional consolidation therapy
    • Education Catalog
      • State of the Science in Ensuring a Donor for All
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
      • Overcoming Challenges in Cell and Gene Therapy Trials Part 2
      • Overcoming Challenges in Cell and Gene Therapy Trials Part 1
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • Early Complications
  • Vaccinations
  • Long-Term Care Guidelines
  • Chronic GVHD
  • Post-Transplant Guidelines

Vaccinations


Research Spotlight
  • A safe and effective shared care approach after allogeneic HCT could be a new standard of care

    December 2022

  • Lack of collaborative relationships between physician teams associated with HCT care decisions

    April 2022

  • Haploidentical HCT is viable alternative to matched sibling HCT in patients with AML in CR1

    July 2019

  • Post-Transplant Care
  • Vaccinations
  • Email
  • Print This Page

Related Resources

  • Post-HCT Care Education
  • Long-Term Care Guidelines
  • Chronic GVHD

Patient Resources

  • Post-Bone Marrow Transplant Care Guidelines
  • Allogeneic Transplant Process Booklet
  • Transplant Basics Videos

Vaccinations After Hematopoietic Cell Transplant

Routine administration of vaccinations is vital for prevention of infectious complications in hematopoietic cell transplant recipients.

Consensus Guidelines

Hematopoietic cell transplant recipients may remain immunocompromised far beyond 2 years post-transplant, especially individuals with chronic graft-versus-host disease (GVHD). Therefore, post-transplant patients should be routinely revaccinated after transplant until they regain immune competence.

The vaccination schedule below is based on international consensus guidelines for preventing infectious complications among all transplant recipients and is recommended for both autologous and allogeneic hematopoietic cell transplant (HCT) recipients. [1,2,3]

These recommended vaccinations are also included in our HCT Guidelines.

  • View Long-Term Care Guidelines (PDF)
  • Order a print version or access HCT Guidelines mobile app

Recommended Vaccinations/Schedulea


Pneumococcal Conjugate (PCV)

  • Recommended for use after HCT: Yes
  • Time post-HCT to initiate vaccine: 3-6 months
  • No. of doses: 3-4b

Tetanus, Diphtheria, Acellular Pertussisc

  • Recommended for use after HCT: Yes
  • Time post-HCT to initiate vaccine: 3-6 months
  • No. of doses: 3d

Haemophilus Influenzae Conjugate

  • Recommended for use after HCT: Yes
  • Time post-HCT to initiate vaccine: 6-12 months
  • No. of doses: 3

Meningococcal Conjugate

  • Recommended for use after HCT: Follow country recommendations for general population
  • Time post-HCT to initiate vaccine: 6-12 months
  • No. of doses: 1

Inactivated Polio

  • Recommended for use after HCT: Yes
  • Time post-HCT to initiate vaccine: 6-12 months
  • No. of doses: 3

Recombinant Hepatitis B

  • Recommended for use after HCT: Follow country recommendations for general population
  • Time post-HCT to initiate vaccine: 6-12 months
  • No. of doses: 3

Inactivated Influenza

  • Recommended for use after HCT: Yearly
  • Time post-HCT to initiate vaccine: 4-6 months
  • No. of doses: 1-2e

Measles-Mumps-Rubella (livef,g)

  • Recommended for use after HCT: Measles: All children and seronegative adults
  • Time post-HCT to initiate vaccine: 24 months
  • No. of doses: 1-2h

Notes:

a) A uniform specific interval between doses cannot be recommended, as various intervals have been used in studies. As a general guideline, a minimum of 1 month between doses may be reasonable.

b) Following the primary series of three PCV doses, a dose of the 23-valent polysaccharide pneumococcal vaccine (PPSV23) to broaden the immune response might be given. For patients with chronic GVHD who are likely to respond poorly to PPSV23, a fourth dose of the PCV should be considered instead of PPSV23.

c) DTaP (diphtheria tetanus pertussis vaccine) is preferred, however, if only Tdap (tetanus toxoid-reduced diphtheria-toxoid reduced acellular pertussis vaccine) is available (for example, because DTaP is not licensed for adults), administer Tdap. Acellular pertussis vaccine is preferred, but the whole-cell pertussis vaccine should be used if it is the only pertussis vaccine available.

d) See references for consideration of an additional dose(s) of Tdap for older children and adults.

For children <9 years of age, two doses are recommended yearly between transplant and 9 years of age.

f) Measles, mumps and rubella vaccines are usually given together as a combination vaccine. In females with pregnancy potential, vaccination with rubella vaccine either as a single or a combination vaccine is indicated.

g) Not recommended <24 months post-HCT, in patients with active GVHD, and in patients on immune suppression.

h) In children, two doses are favored.

See reference [2] for vaccinations considered optional or not recommended for transplant recipients and for vaccinations for family, close contacts and health care workers.

References

  1. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT) and Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). Co-published in Biol Blood Marrow Transplant, 2012, 18(3): 348-371; Bone Marrow Transplant, 2012, 47(3): 337-341; and Hematol Oncol Stem Cell Ther, 2012, 5(1): 1-30. Access
  2. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 2009; 15(10): 1143-1238. Access
  3. Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009; 44(8): 521-526. Access
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation
  • Local Provider Partnership Program

Contact Us

National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright